Lisa. you, Thank
existing shareholders with joining. everyone outreach for thrilled are To us, you our as we have and to you We with new interactions thank join call and potential expand to the on analysts. investors Opiant
may for be Opiant overview who begin new you I’d with story. like to brief of of a to the those
drug addictions medicines to is mission of the Our and overdose. treat development best-in-class
Nasal in NARCAN decline, Recently, widespread Pharma overdose reported XXXX. by the it we of opioid from is Spray may we EBS, are deaths NIDA in to and Nasal Adapt that that are $XXX licensed particular, XXXX, started to is Nasal – it very a its Emergent of Adapt NIH, to reverse and in the government brands revenue Our or here from NARCAN NARCAN, at has led due funded and from We well acquired NARCAN It at been BARDA. royalties largely Spray. initial it the decline it to which from developed development. stream Spray this of use here and overdose at sales the highlighting BioSolutions, programs license opioid Opiant, welcome. to believed value proud have have Opiant, million
work a and crisis remains U.S. proportion is here opioid of deaths into of easier opioids and the opioid significant in obtain The there from overdose the overdose rise. continues XX,XXX deaths, X overdose And It opioid Nevertheless, million opioids. fentanyl continues prescription people are has and to that crisis. is ravage and public one our suffering from over was the really extension evolved health not in America, fentanyl Therefore, related. addiction. opioid done. fentanyl crisis And to other now synthetic with XX% to opioid XXXX,
need exists substantial length increase antagonists to rapid to critical due stronger overdoses. the opioid a to fentanyl-related save longer-acting access is – While lives, naloxone opioid in
been receive NARCAN. co-prescribing present a of naloxone. We our received higher The date potent the issue. considered sales an This from an opioid are opioid when in has of of prescription driver This laws from is prescription this growing on to primarily to supported royalty the states. call. increase Spray at status overdose. are nasal I’ll nine generated in would risk longer-acting Nasal being patients advance sales recent help NARCAN for The later means OPNTXXX that the developing used data the and an to we in now net patients nalmefene more our implemented A pipeline. are NARCAN receiving update also than address its provide royalties
for example, duration. they required naloxone New opioid. an opioid alongside co-prescribing Mexico more receive alongside five Recently, prescriptions sleeping prescription medication also or of For days when every single
to our pipeline. on Moving
cannabis-containing like Acute the with or in program, are for often Cannabinoid to Overdose referred combination ACO linked expanded our matters ingestion from treatment even is in-licensed by we in THC and our as ingested alone are where recently with market and expensive We the discuss cannabinoids synthetic in manufacturing and to Sanofi. of linked KX To or Drinabant, relationship other less expanded both been Sanofi. I’d to These potent, in edibles of containing we most synthetic these more and substances. easily First, make of the often to worse, OPNTXXX synthetic local Spice. to partnership large deaths XXXX, December, have products. ACO often Drinabant Sanofi quantities cannabinoids, obtained, ACO, include recently cannabinoids drugs when
U.S. data National which for of the the of increase for to visits America. The is is already for in and ACO According the resulted over year, monitoring with Emergency market rooms, in expected X Opiant. ACO is room length rise to We department cannabis a view acquiring opportunity latest Department North XXXX in intense in substantial million reported number this emergency XXXX, in of stay. legalization the indication emergency overburdening and as emergency visits samples, XXXX available.
brownies. ingested from Sadly, many cookies, visits of who children candies or THC-containing ER resembling products, are these
As for of prepared. cannabis anticipate a which crisis we cannabis society the not legalization increases, is potential
has well know program. no This approved currently for ACO, excited are our Importantly, need and more patients treatment to development. Sanofi, shown in Drinabant oral received I currently for conducted increasing there that us of no are ACO has be studies Phase XXX than orally. II we OPNTXXX others Drinabant Phase treatments XX for about been taken and by safe up and tolerated, In volunteers and weeks. to when
blocked. We formulation that development establishing of objective a and THC subjects and it rapidly will can year oral proof given in emergency and study a in Opiant this so reverse injection, inhaled in intend principal, the addition, Drinabant room ACO initiate an of clinical trials of as Drinabant to symptoms studies in XXXX. reformulate both then setting. In XX subjective THC, effects were were an
provide an that, update quarter, to our for be let this third PK we topline the year. me that study With OPNTXXX OPNTXXX. I’m expect will data report pleased and to underway on in now report
to remains NDA file and on objective next year, so. Our an do we remain to track
As Spray. a NARCAN with therefore, XXX(b)(X) And confirmed development pathway a reminder, have we FDA. to regulatory the a pathway Nasal similar
address a event OPNTXXX $X.X has countermeasure medical $X.X OPNTXXX million developments U.S. by the government and In government as grant To up financial BARDA. addition, implications David a contract million collective of these will we to to of validated say of with are that continued for its let grateful me funds, accelerate the but in through these development. a a attack. NIDA the agencies from U.S. have been the fentanyl in the key partnership just from chemical very
to Disorder, to we’re study, Alcohol Phase later the Use for which begin enrolling study this preparations AUD, selection for formulation on Nasal naltrexone, year. have and a developing we Moving or initiated expect patients II OPNTXXX. and begun
second We anticipate continue to II of the the Phase the study half completion XXXX. of by
a with OPNTXXX life a may longer naloxone also potential treatment overdose. As as essentially for yes, – with to term, potency naloxone, opioid greater identical personal than a have reminder,
presented leaders are sponsored Skolnick, Intranasal our Scientific both Dr. Respiratory the advancing a to investment to In Phil busy of addition story NIDA countermeasures on pipeline, developing perspective, Nalmefene we the Chief industry Depression our telling discussion August Officer, our development medical the rescue an community. Meeting and to Opioid-Induced on at industry by From six.
by present opportunity over David conferences I to next the Opiant Fargo, the Wells and will have and few events Wainwright In institutional sponsored investors Cantor at include H.C. months, the story to addition, Fitzgerald. that
will be presenting Raton, I the XXth Summit Annual Boca Additionally, in at Florida. CNS
further event investors The hosting will agenda in and analysts our today event. programs with that and Moreover, of highlights of the we community each be the R&D look to coming I’m will for at XX. on an excited to investments announce forward this weeks, announced Opiant be October sharing
clinical the million in discuss now David the which cash position BARDA program, Opiant or million NIDA in support include funds I support financial strong majority of ask results. our from remaining $XX.X not at does will our contract the – June our in a sorry, $X.X grant. Finally, developments that, With David? of the to remains XXXX, financial XX, of approximately of with finally,
